S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
PLSH · PANACEA LIFE SCIENCES HLDGS INC
OTC MARKETS - Real Time Price • USD
Panacea Life Sciences Holdings Inc (PLSH)
OTC MARKETS
Pharmaceuticals
$0.07
+0.00
(+0.00%)
● Overnight
DAY'S RANGE
$0.07
$0.07
$0.07
52-WEEK RANGE
$0.07
$0.02
$0.20
What's happening
- PLSH is up 0.00% today, trading at $0.07. — Live quote
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
PLSH
+39.20%
vs S&P 500
+36.41%
3-MONTH RETURN
PLSH
+145.07%
Valuation Measures & Ratios
Enterprise Value4$20.4M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)1.71
Price / Book71.31
EV4 / Revenue7.36
EV4 / EBITDA—
Profit Margin-277.35%
Operating Margin-192.10%
Return on Equity (ROE8)-181.63%
Return on Assets (ROA9)-42.51%
Avg Volume (3M)25,390
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short8,446
Change from Prior Settlement-0.12%
% of Float—
Days to Cover (Short Ratio)4.18
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-15. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 55.9% on the provider's reported measure. Finnhub fundamentals ↗
Potential concerns
- Net profit margin is -277.4%. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2024-05-16; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on PLSH
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Mar '24 | Sep '23 | Jun '23 | Mar '23 | Sep '22 | Jun '22 | Mar '22 | Sep '21 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $347.9K | $399.1K | $677.5K | $366.2K | $469.5K | $466.5K | $588.0K |
| Gross profit | $666.2K | $146.6K | $202.8K | $225.6K | $47.3K | $138.0K | $100.4K | $283.0K |
| Operating income | -$1.1M | -$1.4M | -$1.1M | -$1.3M | -$1.4M | -$1.2M | -$1.6M | -$1.3M |
| Net income | -$1.4M | -$2.2M | -$1.9M | -$1.8M | -$2.7M | -$2.0M | -$2.8M | -$3.1M |
| EPS (diluted) | $-0.09 | $-0.13 | $-0.11 | $-0.12 | $-0.18 | $-0.13 | $-0.19 | — |
| EPS (basic) | $-0.09 | $-0.13 | $-0.11 | $-0.12 | $-0.18 | $-0.13 | $-0.16 | $-0.18 |
| Operating margin | -$100 | -$407 | -$269 | -$190 | -$379 | -$264 | -$353 | -$214 |
| Net margin | -$137 | -$618 | -$467 | -$264 | -$736 | -$418 | -$596 | -$525 |
Balance sheet
| Line item | Mar '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | Dec '22 | Sep '22 | Jun '22 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $17.4M | $18.0M | $18.7M | $17.9M | $18.6M | $19.5M | $20.0M | $22.0M |
| Total liabilities | $27.0M | $26.3M | $24.8M | $23.4M | $22.4M | $21.6M | $20.4M | $19.7M |
| Stockholders' equity | -$9.6M | -$8.3M | -$6.1M | -$5.6M | -$3.8M | -$2.1M | -$439.9K | $2.3M |
| Total current assets | $4.6M | $4.7M | $5.9M | $5.7M | $5.9M | $6.4M | $6.5M | $8.1M |
| Total current liabilities | $20.4M | $19.4M | $18.5M | $17.0M | $15.9M | $15.1M | $13.8M | $13.1M |
| Cash & equivalents | $107.6K | $100.9K | $1.5K | $8.2K | $73.2K | $7.0K | $36.8K | $36.5K |
| Marketable securities (current) | $9.5K | $14.9K | $78.4K | $460.4K | $925.1K | $1.1M | $1.1M | $2.6M |
| Accounts receivable | $270.9K | $264.0K | $308.8K | $272.1K | $274.8K | $206.1K | $221.9K | $219.6K |
| Inventory | $4.1M | $4.0M | $4.7M | $4.4M | $4.1M | $4.4M | $4.4M | $4.5M |
| Other current assets | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $6.1M | $6.4M | $6.9M | $6.9M | $7.3M | $7.7M | $8.0M | $8.2M |
| Goodwill | $3.0M | $3.0M | $3.0M | $2.2M | $2.2M | $2.2M | $2.2M | $2.2M |
| Intangible assets | $3.0M | $3.0M | — | — | — | $2.2M | $15.4K | $30.7K |
| Accounts payable | — | — | — | — | — | — | — | — |
| Accrued liabilities | — | — | — | $592.8K | — | $282.9K | — | — |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Short-term debt | — | — | — | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | $3.6M | $3.6M | $3.6M | $3.6M | $3.6M | $3.6M | $3.5M | $3.5M |
| Common stock & paid-in capital | $1.8K | $1.8K | $1.8K | $1.8K | $1.6K | $1.5K | $1.5K | $1.5K |
| Retained earnings | -$35.4M | -$33.9M | -$31.7M | -$29.6M | -$27.7M | -$25.9M | -$24.2M | -$21.5M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — | — | — | — |
Cash flow
| Line item | Mar '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | Dec '22 | Sep '22 | Jun '22 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$357.1K | $1.6K | -$728.9K | -$483.3K | -$313.9K | -$523.0K | -$711.1K | -$729.5K |
| Investing cash flow | -$5.0K | -$17.9K | -$22.8K | -$9.3K | -$15.2K | -$98.8K | -$127.4K | $39.0K |
| Financing cash flow | $368.8K | $115.8K | $745.0K | $427.6K | $395.4K | $592.0K | $838.7K | $671.0K |
| Free cash flow | -$362.1K | -$39.2K | — | -$492.7K | -$329.1K | -$621.8K | -$838.4K | -$737.3K |
| Capital expenditures | $5.0K | $40.8K | — | $9.3K | $15.2K | $98.8K | $127.4K | $7.9K |
| Depreciation & amortization | — | — | — | — | — | — | — | — |
| Share-based compensation | — | — | — | — | — | — | — | — |
| Change in accounts receivable | $6.9K | -$544.8K | $47.6K | -$2.7K | $68.7K | -$15.8K | $2.4K | $56.9K |
| Change in inventory | $49.3K | -$140.0K | -$66.4K | $262.7K | -$353.7K | $36.6K | -$68.3K | $155.7K |
| Change in accounts payable | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 |
|---|---|---|---|---|---|
| Revenue | $2.4M | $1.6M | $2.1M | — | — |
| Gross profit | $1.1M | $396.5K | $540.6K | $2.0M | -$1.7M |
| Operating income | -$5.5M | -$5.7M | -$5.9M | -$5.3M | -$10.7M |
| Net income | -$8.0M | -$9.1M | -$4.8M | -$5.2M | -$10.0M |
| EPS (diluted) | $-0.48 | $-0.62 | — | — | — |
| EPS (basic) | $-0.48 | $-0.62 | $-0.28 | — | — |
| Operating margin | -$233 | -$347 | -$288 | — | — |
| Net margin | -$336 | -$562 | -$232 | — | — |
Balance sheet
| Line item | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Mar '20 |
|---|---|---|---|---|---|
| Total assets | $18.0M | $19.5M | $23.8M | $31.4M | $6.8M |
| Total liabilities | $26.3M | $21.6M | $16.7M | $24.7M | $5.0M |
| Stockholders' equity | -$8.3M | -$2.1M | $7.1M | $6.7M | — |
| Total current assets | $4.7M | $6.4M | $9.1M | $11.5M | $1.7M |
| Total current liabilities | $19.4M | $15.1M | $10.1M | $18.3M | $4.8M |
| Cash & equivalents | $100.9K | $7.0K | $19.8K | $84.4K | — |
| Marketable securities (current) | $14.9K | $1.1M | $3.8M | $2.9M | — |
| Accounts receivable | $264.0K | $206.1K | $244.5K | $147.3K | — |
| Inventory | $4.0M | $4.4M | $4.3M | $8.4M | — |
| Property, plant & equipment | $6.4M | $7.7M | $8.8M | $13.6M | — |
| Goodwill | $3.0M | $2.2M | $2.2M | $2.2M | — |
| Intangible assets | $3.0M | $2.2M | $61.4K | $122.8K | — |
| Accounts payable | — | — | — | $2.0M | — |
| Accrued liabilities | — | — | — | $620.4K | — |
| Deferred revenue (current) | — | — | — | $0 | — |
| Short-term debt | — | — | — | $696.3K | — |
| Long-term debt | — | — | — | $335.5K | — |
| Other non-current liabilities | $3.6M | $3.6M | — | — | — |
| Common stock & paid-in capital | $1.8K | $1.5K | $1.4K | $1.7K | — |
| Retained earnings | -$33.9M | -$25.9M | -$16.8M | -$12.0M | — |
| Accumulated other comprehensive income (loss) | — | — | — | — | — |
Cash flow
| Line item | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 |
|---|---|---|---|---|---|
| Operating cash flow | -$1.5M | -$2.4M | -$3.9M | -$7.6M | -$5.7M |
| Investing cash flow | -$65.3K | -$197.0K | $522.5K | -$3.1M | -$2.0M |
| Financing cash flow | $1.7M | $2.6M | $3.3M | $2.3M | $7.8M |
| Free cash flow | -$1.6M | -$2.6M | -$4.1M | -$10.8M | -$6.3M |
| Capital expenditures | $65.3K | $243.8K | $162.9K | $3.2M | $541.2K |
| Depreciation & amortization | — | — | — | — | — |
| Share-based compensation | — | — | — | $1.3M | $3.8M |
| Change in accounts receivable | -$431.3K | -$38.4K | $97.2K | -$151.7K | $88.3K |
| Change in inventory | -$297.4K | $184.4K | $547.9K | $5.0M | $2.9M |
| Change in accounts payable | — | — | — | $684.6K | $519.0K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding PLSH as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2019-06-24 to 2023-09-18
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Buttorff Leslie | CEO | Open market purchase | 2023-09-18 | 20,000 |
| Wert Lawrence | Director | Open market purchase | 2022-08-11 | 5,000 |
| Berman Nathan Joel | CONTROLLER & PRIN ACTNG OFCR | Grant / award | 2021-06-30 | 496,957 |
| Alberttis Alvaro Daniel | CHIEF OPERATING OFFICER | Grant / award | 2021-01-22 | 2,039,241 |
| Johnson Andrew L. | CHIEF GROWTH OFFICER | Grant / award | 2021-01-22 | 8,186,240 |
| Puzder Ken | CHIEF FINANCIAL OFFICER | Grant / award | 2020-02-01 | 250,000 |
| Ceed2Med LLC | Reporting person | Other acquisition/disposition | 2019-12-11 | 1,200,000 |
| Price John C | Reporting person | Grant / award | 2019-11-20 | 100,000 |
| Thompson Jeffrey M | Reporting person | Grant / award | 2019-11-20 | 100,000 |
| ESVAL KEVIN JAMES | Reporting person | Grant / award | 2019-11-20 | 100,000 |
| Schwartz Steven A | Reporting person | Grant / award | 2019-06-24 | 98,040 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:20 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2024-05-16 | 8-K | 2024-05-13 | View on SEC.gov → |
| 2024-05-07 | 8-K | 2024-05-03 | View on SEC.gov → |
| 2024-05-06 | 10-Q | 2024-03-31 | View on SEC.gov → |
| 2024-04-01 | 10-K | 2023-12-31 | View on SEC.gov → |
| 2024-03-07 | 8-K | 2024-03-05 | View on SEC.gov → |
| 2024-02-05 | 8-K | 2024-01-29 | View on SEC.gov → |
| 2023-11-14 | 10-Q | 2023-09-30 | View on SEC.gov → |
| 2023-10-05 | 8-K | 2023-10-05 | View on SEC.gov → |
| 2023-10-02 | 8-K | 2023-10-02 | View on SEC.gov → |
| 2023-09-20 | 4 | 2023-09-18 | View on SEC.gov → |
| 2023-08-15 | 10-Q | 2023-06-30 | View on SEC.gov → |
| 2023-07-10 | 8-K | 2023-07-03 | View on SEC.gov → |
Recent news
Headlines about PLSH (PANACEA LIFE SCIENCES HLDGS INC). Links open the publisher — we don’t host full articles.
-
Panacea Life Sciences Holdings (OTCID: PLSH) and Benivita Inc. Launch Benivita PLSH -- a New Era in Direct-to-Consumer Virtual Benefits
Yahoo Finance · 2025-11-18 -
Panacea Life Sciences will acquire natural health and wellness chain locations in Florida
Seeking Alpha · 2023-07-10
No headlines in this category right now — try “All”.